Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSQ-001EX in Advanced Solid Tumors
NCT06237881Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of KSQ-001EX in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events, Dose-limiting toxicities and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
KSQ-001EX
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06237881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237881.